New York, Jan 15, 2026, 13:00 ET — Regular session
- Thermo Fisher shares gained roughly 0.7% by midday trading.
- CEO Marc Casper reported the company secured contracts as drugmakers move production back to the United States.
- Investors are eyeing the Jan. 29 results for clues on timing, demand, and what to expect in 2026.
Thermo Fisher Scientific shares rose roughly 0.7% to hit $626.17 by midday Thursday, building on gains from the day before.
CEO Marc Casper said Thermo Fisher’s pharmaceutical services have secured contracts to help clients move production from Europe and Asia back to the U.S. “There’s a very big focus on reshoring more production and activity to the U.S.,” he noted, calling it a tailwind for 2027 and 2028. Casper added that Thermo’s acquisition of Sanofi’s Ridgefield, New Jersey facility aims to boost capacity in support of this shift. Reuters
Why it matters now: investors are wrestling with whether demand in life-science tools and outsourced drug manufacturing is leveling off, following patchy spending in biotech and pharma. Firm insights on factory shifts and long-term projects could reshape trader expectations for 2026 compared to later years.
Thermo Fisher ended Wednesday’s session up 2.43%, closing at $621.83 and breaking a brief losing streak. Trading volume surpassed its 50-day average, according to MarketWatch data.
Thermo’s pharma services division acts as a contractor for drugmakers, managing development and manufacturing tasks that clients prefer not to perform internally. Projects often begin on a small scale but can ramp up if a drug progresses through trials or if a company opts to shift production nearer to its sales markets.
Timing is the market’s next big question. Reshoring often involves years of build-out and qualification before steady output kicks in. Investors want to hear any clue on how fast contracts signed now will turn into actual revenue.
Thermo Fisher is set to release its quarterly earnings before U.S. markets open on Jan. 29. The company will also hold a conference call that same morning, according to a statement.
There are plenty of risks here. If policy pressure fades, or clients delay plant relocations due to costs, approvals, or shifts in demand, the short-term boost might fall well short of the hype.
Jan. 29 is the date to watch. Investors will look for insights on pharma services orders and instruments demand in 2026, along with whether the company’s outlook lines up with this week’s sharp rise in the stock.
